ArticleFrontiers in pharmacology2025
Liangfang Wenjing decoction regulates endoplasmic reticulum stress-mediated apoptosis to alleviate uterine microvascular injury in cold-stressed rats.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cold exposure can induce microvascular damage, which in turn contributes to various gynecological disorders. Liangfang Wenjing Decoction (LFWJD), a classical botanical drug prescription, has long been used to treat gynecological diseases caused by cold through improving microvascular injury. Nevertheless, its underlying therapeutic mechanism is still unclear. This study aimed to elucidate the effects of cold stress on uterine microvessels and to explore the pharmacological mechanisms through which LFWJD mitigates uterine microvascular injury. Methods: UPLC-MS/MS analysis was used to identify the major metabolites in LFWJD. A rat cold stress model was established using ice-water bath treatment, to investigate the mechanisms by which LFWJD ameliorates uterine microvascular injury. The study assessed several parameters, including the estrous cycle of rats, hemorheology indices, real-time blood flow in the auricle and uterine surfaces, and uterine arterial hemodynamics. Uterine histopathology and ultrastructural changes in vascular endothelial cells were observed. Serum and uterine tissue endothelial factors were quantified by ELISA, while apoptosis in uterine and vascular endothelial cells was evaluated using TUNEL staining. Western blotting and immunofluorescence were performed to detect the expression of apoptosis-related proteins, endoplasmic reticulum stress (ERS) marker proteins, and proteins associated with the IRE1α/ASK1/JNK and IRE1α/XBP1s signaling pathways. Results: Treatment with LFWJD for 21 days restored the estrous cycle in cold-stressed rats and improved uterine histopathology, as evidenced by an increased number of glands and thickening of the endometrium. LFWJD also enhanced blood perfusion in the auricle and uterine surface, regulated vascular endothelial factors (ET-1, NO, vWF, and TM), and repaired the ultrastructural integrity of endothelial cells. Moreover, it reduced apoptosis in uterine tissue and vascular endothelial cells by downregulating the expression of pro-apoptotic proteins (Bax, and cleaved caspase3) and ERS-related factors (GRP78, CHOP, XBP1s, p-IRE1α, p-ASK1, and p-JNK), while upregulating the anti-apoptotic protein Bcl-2 protein. Collectively, these pharmacological effects contributed to the alleviation of uterine microvascular injury in the uterus of cold-stressed rats. Conclusion: LFWJD may exert its pharmacological effects by inhibiting the expression of ERS-related signaling pathway proteins and alleviating apoptosis, thereby improving uterine microvascular injury. This will provide an experimental foundation for the potential clinical application of LFWJD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.